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ABSTRACT
Trypanosoma brucei, the causative agent of sleeping
sickness (Human African Trypanosomiasis, HAT),
contains a kinetoplast with the mitochondrial DNA
(kDNA), comprising of >70% AT base pairs. This
has prompted studies of drugs interacting with
AT-rich DNA, such as the N-phenylbenzamide bis(2-
aminoimidazoline) derivatives 1 [4-((4,5-dihydro-1H-
imidazol-2-yl)amino)-N-(4-((4,5-dihydro-1H-imidazol-
2-yl)amino)phenyl)benzamide dihydrochloride]
and 2 [N-(3-chloro-4-((4,5-dihydro-1H-imidazol-2-
yl)amino)phenyl)-4-((4,5-dihydro-1H-imidazol-2-
yl)amino)benzamide] as potential drugs for HAT.
Both compounds show in vitro effects against T.
brucei and in vivo curative activity in a mouse model
of HAT. The main objective was to identify their
cellular target inside the parasite. We were able to
demonstrate that the compounds have a clear effect
on the S-phase of T. brucei cell cycle by inflicting
specific damage on the kinetoplast. Surface plas-
mon resonance (SPR)–biosensor experiments show
that the drug can displace HMG box-containing pro-
teins essential for kDNA function from their kDNA
binding sites. The crystal structure of the complex
of the oligonucleotide d[AAATTT]2 with compound
1 solved at 1.25 A˚ (PDB-ID: 5LIT) shows that the
drug covers the minor groove of DNA, displaces
bound water and interacts with neighbouring DNA
molecules as a cross-linking agent. We conclude
that 1 and 2 are powerful trypanocides that act
directly on the kinetoplast, a structure unique to the
order Kinetoplastida.
INTRODUCTION
Human African trypanosomiasis (HAT), also known as
sleeping sickness, is a neglected tropical disease that is
almost invariably fatal if left untreated. It is caused by
subspecies of the protozoan parasite Trypanosoma brucei
which is transmitted to humans by the tsetse fly vector.
Approximately 55 million people distributed over a surface
of 340 000 km2 in 33 sub-Saharan Africa countries are
estimated to be at different levels of risk of contracting
sleeping sickness (1). Most of the affected populations
live in remote rural areas with limited access to health
services, which complicates the diagnosis and treatment
of cases in Africa’s poorest countries. The current drugs
used to treat HAT (suramin, pentamidine, melarsoprol and
nifurtimox-eflornithine combination therapy, or NECT)
are toxic and sometime ineffective due to the appearance of
drug-resistant strains of T. brucei (2). In the last decades,
efforts have been made to discover improved drugs to treat
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Figure 1. Structure of compounds 1 and 2.
HAT (1). In previous reports, we have shown that com-
pound 1, 4-((4,5-dihydro-1H-imidazol-2-yl)amino)-N-(4-
((4,5-dihydro-1H-imidazol-2-yl)amino)phenyl)benzamide
dihydrochloride, and a series of chloro, fluoro and pyridinyl
derivatives, displayed excellent antitrypanosomal activity
in vitro and were selective toward Trypanosoma brucei
(3). Compound 1 was curative by oral administration
in a mouse model of acute T. b. rhodesiense infection (4)
demonstrating a great potential as chemotherapeutic agent.
Compound 2, a chloro analogue closely related to 1, was
recently shown to be more potent than 1 in vitro (3) (Figure
1).
Previous studies by our group (5–10) and by others (11–
15) have shown that bis(2-aminoimidazoline) drugs of this
class are DNA minor groove binders with excellent affinity
and selectivity toward AT-rich DNA regions. Since tran-
scription and activity of other DNA-dependent enzymes
may all be inhibited by DNA binders (16,17), this interac-
tion is thought to be primarily responsible for the antitry-
panosomal activity of this class of compounds. In fact, the
dicationic nature of these molecules is the driving force that
compels them to accumulate in the charged mitochondrion
of the parasite (i.e. negative inside); the high local concen-
tration aids their anti-parasite effects by binding to DNA
or mitochondrial proteins, as shown for other trypanocidal
cations (18–21).
For many years, our group has focused on a series of
bis(2-aminoimidazolines) and their interactions with the
minor groove of DNA, almost exclusively with adenine and
thymine (AT) sequences. Previous studies have shown the
3D structure of minor groove-binding drugs in complex
with AT-rich oligonucleotides, which interact with neigh-
bouring DNA molecules, e.g. pentamidine in complex with
AT alternating sequences (22) and CD27 with A-tracks (8).
Here, we report a detailed study of the interaction of
two new drugs, the bis(2-aminoimidazolinium) compounds
1 and 2, with AT-rich DNA sequences. Since kinetoplast
DNA has a high content of AT-rich sequences, we aimed
to discover whether parasite DNA was a target for these
compounds inside the cell. We evaluated the in vitro and in
vivo effect of these drugs against bloodstream form T. bru-
cei and, by a combination of flow cytometry and imaging
techniques, confirmed their cellular target as kDNA.
We also analysed the kDNA genome and found it abun-
dant in AAA or TTT sequences (see Supplementary Figure
S1, available as Supplementary data), which could serve as
possible binding sites for the drugs. The X-ray crystal struc-
ture of this DNA sequence in complex with compound 1
gave us a model for the interaction at atomic resolution
of 1.25 A˚. In support of drug action through direct bind-
ing to kDNA we demonstrated that compound 2 displaces
the human proteins HMGA1a and HMGB1 from DNA.
This result is of particular interest to understand its try-
panocidal activity because the mitochondrial HMG-box
protein TbKAP6, which is similar to HMGB1, is essential
for kDNA replication and maintenance (23).
MATERIALS AND METHODS
Strains and cultures
All parasite cultures used in this study were Trypanosoma
brucei brucei bloodstream forms (BF) of strain Lister
427/MiTat1.2 (wild-type, Tb427WT) or of T. b. brucei
ISMR1. Strain ISMR1 is a clonal, Tb427WT-derived dys-
kinetoplastid cell line, adapted to in vitro growth in 1 Mof
isometamidium (ISM) by stepwise increases in the medium
concentration of the drug (19). All strains were cultured un-
der standard conditions (37◦C, 5% CO2) in HMI-9 medium
(Gibco, UK) supplemented with 2 mM -mercaptoethanol
(Sigma-Aldrich) and 10% fetal bovine serum (FBS; Gibco)
exactly as described (24).
Drug sensitivity assays
Fifty percent effective concentrations (EC50) were deter-
mined using the fluorescence viability indicator dye Alamar
Blue (resazurin sodium salt, Sigma-Aldrich) as described
(25), with small modifications. Resazurin is metabolized by
live cells to resorufin and the fluorescent signal generated is
thus proportionate to the number of live cells (25). Thus, the
assay measures cell numbers rather than detecting cell lysis,
and low cell numbers can be the result of growth inhibition/
cell cycle arrest or of a lethal effect of the test compound
on part of the cell population. Doubling dilutions of test
compounds were prepared over two rows of a 96-well plate,
leaving the last well drug-free as a control, before the addi-
tion of an equal volume of cell suspension to each well, to
get a final cell density of 1 × 104 cells/ml. The plates were
incubated at 37◦C/5% CO2 for 72 h after which 20 l of re-
sazurin solution (125 g/ml in phosphate-buffered saline,
pH 7.4) was added followed by another incubation for 24
h. Fluorescence was determined using a FLUOstar Optima
plate reader (BMGLabtech, Durham,NC,USA), at excita-
tion and emission wavelengths of 530 and 590 nm, respec-
tively. Data were analysed and plotted to a sigmoid curve
with variable slope using Prism 5.0 (GraphPad, San Diego,
CA, USA).
Effect of bis(2-aminoimidazolinium) N-phenylbenzamide
compounds on growth of BF T. brucei
The effects of the bis(2-aminoimidazolinium) compounds
1 and 2 on growth of BF Trypanosoma brucei brucei strain
Lister 427 were investigated by incubating cultures under
standard conditions (HMI-9/10% FBS; 37◦C, 5% CO2) in
the presence or absence of 0.5, 1, 2.5 and 5 times their EC50
values for up to 48 h. Cells were seeded at a density of 2 ×
104 cells/ml using a haemocytometer. Samples were taken
in triplicate at the following times (h) after initiation of the
experiment: 0, 4, 8, 24, 36, 48.
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Assessment of cell cycle progression in T. brucei
Fluorescence microscopy. Nuclei and kinetoplasts were vi-
sualized by using the fluorescent dye 4’,6-diamidino-2-
phenylindole (DAPI) on BF trypanosomes after fixation. 50
l of cells at 2 × 106 cells/ml were spread onto a glass mi-
croscope slide, left to dry in a fume hood and fixed in 4%
paraformaldehyde in fresh PBS for 10 min at room temper-
ature. The slides were washed with 1 × PBS. The PBS was
gently removed by inclining the slide on a soft tissue and a
drop of Vectashied® mounting medium containing DAPI
dihydrochloride (Vector Laboratories, USA) was placed on
the slide before covering with a cover slip. The slide was then
viewed under UV light on a Zeiss Axioskop 2 fluorescent
microscope (Carl Zeiss Microscopy, USA). Five hundred
cells were recorded for each sample, and scored for DNA
configuration following these groups: 1N1K, 1N2K, 2N2K
(Early) and 2N2K (Late) (N, nucleus; K, kinetoplast). The
effect of test compounds on DNA configuration was deter-
mined at 0, 8 and 24 h; untreated cultures served as control.
Flow cytometry. DNA content of BF trypanosomes was
measured by flow cytometry using the fluorescent dye pro-
pidium iodide (PI), as described (18,26). Samples were anal-
ysed using a BD FACSCalibur™ system (BD Biosciences).
Data was acquired from the FSC, SSC, FL2-W and FL2-A
detectors using BD CellQuest™ software (BD Biosciences),
and further analysed and graphically represented using the
C©FlowJo 10.2 software.
Mitochondrial membrane potential
The mitochondrial membrane potential of treated and un-
treated cells was assessed by using tetramethylrhodamine
ethyl ester (TMRE) following a protocol previously de-
scribed (18). Samples were analysed using a BD FACSCal-
ibur™ system (BD Biosciences). Data were acquired from
the FL2-height detector using BD CellQuest™ software
(BDBiosciences), and further analyzed and graphically rep-
resented using the C©FlowJo software, version 10.2. Valino-
mycin (100 nM) and troglitazone (10 M) were employed
as negative (mitochondrial membrane depolarisation) and
positive (mitochondrial membrane hyperpolarisation) con-
trols, respectively (27). Mitochondrial membrane potential
was determined at 0, 3, 6 and 12 h. The detector was cali-
brated so that the peak of control cells (Tb427WT not ex-
posed to any test compound) was set at 100 arbitrary units,
i.e. with 50% of cells at >100 A.U. and 50% at <100 A.U.
The data are presented as percent of the cell populationwith
a fluorescence >100 A.U.
Cellular localization of the compound in the BF T. brucei
The localization and distribution of the fluorescent com-
pound 2 in the BF trypanosomes was studied by fluores-
cence microscopy. Trypanosome cultures were grown in
HMI-9/FCS media, cell density was adjusted to 2 × 106
cells/ml and the compound 2 was added to make a concen-
tration of 5 M; a negative control (drug free sample) was
also prepared. 1 ml of sample was taken every time point
and transferred into an empty tube, and 1 l of 1 mM solu-
tion of MitoTracker® Red CMXRos (Thermo Fisher Sci-
entific) in DMSO was added to make a final concentration
of 100 nM. Samples were incubated at 37◦C and 5% CO2
for 5 min. Subsequently, samples were washed with filter-
sterilised 1× PBS and spun at 1500 × g. Pellets were re-
suspended in 50 l of PBS and spread into a glass micro-
scope slide. The cells were dried in a fume hood and fixed
in 4% formaldehyde/PBS fresh for 10 min at room temper-
ature. Cells were permeabilized with cooled methanol for
5–10 min at –20◦C, washed once or twice with 1× PBS
and then washed twice with Hanks’ Balanced Salt Solu-
tion (HBSS). Enough solution 1:30 000 (167 nM) of green-
fluorescent counterstain SYTOX® Green nuclei acid stain
(ThermoFisher Scientific) inHBSS to cover all the cells was
added to the slides and incubated for 15–30 min protected
from light. Finally, cells were washed twice with HBSS and
the slides were covered with a cover slip. The location of the
test compound was determined at 0, 3, 6 and 24 h. The slide
was then viewed under a DeltaVision Core microscope (Im-
age Solutions - Applied Precision, United Kingdom) under
several fluorochromes (blue for 2, green for the SYTOX®
and red for the Mitotracker®), as well as under UV light.
Image acquisitionwas controlled using Zen software (Zeiss)
and SoftWorx software was used for further image process-
ing.
Transmission electron microscopy
Transmission electron microscopy was used to assess the
action of the compounds on T. brucei ultrastructure. Cells
were harvested and the density was adjusted to 2 × 106
cells/ml. The samples incubated 3 and 24 hwith 5Mof the
compound, as well as untreated cells for control were cen-
trifuged at 610 × g for 10 min at room temperature and the
pellet was washed once with 1× PBS and re-suspended in
1 ml of the fixative solution containing 2.5% of glutaralde-
hyde and 4% paraformaldehyde in 0.1 M phosphate buffer
(pH 7.4) and left at 4◦C overnight. Then, samples were cen-
trifuged at 4000 rpm for 8 min and pellet was washed three
timeswith 0.1Mphosphate buffer (pH7.4). Cells were post-
fixed in a solution of 1% osmium tetroxide for 1 h on ice,
and washed with the phosphate buffer to remove excess of
osmium tetroxide. Then, cells were kept in 0.5% uranyl ac-
etate solution for 30 min, washed three times with distilled
water and dehydrated by using a series of increasing con-
centrations of acetone (30, 50, 70, 90 and 100%). Next, cell
infiltration was performed using an epoxy resin. Thin sec-
tions (50–60 nm) were observed in a Tecnai T20 (FEI) at
200 kV.
In vivo activity against T. b. rhodesiense
Compound 2 was assayed in vivo in the STIB900 mouse
model of acute infection. The compound was administered
to a group of four female NMRI mice by intraperitoneal
route using a 4-day treatment regimen of 20 mg/kg/day
using a previously reported protocol (9). Parasitemia was
monitored over a 60-day observation period. Mice were
considered cured when no relapse was detected in the tail
blood over the observation period. The in vivo efficacy stud-
ies were conducted at the Swiss Tropical and Public Health
Institute (Basel) according to the rules and regulations for
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the protection of animal rights of the Swiss ‘Bundesant fu¨r
Veterina¨rwesen’. They were approved by the veterinary of-
fice of Canton Basel-stadt, Switzerland.
Crystallization assays
Synthesis. The deoxyoligonucleotide d[AAATTT]2 was
synthesized at the Pasteur Institute as the ammonium
salt on an automatic synthesizer by the phosphoramidite
method. It was purified by gel filtration and reverse-phase
HPLC. The final concentration was calculated from the
A260 using an extinction coefficient of 89.84 mM−1 cm−1.
The synthesis of 4-((4,5-dihydro-1H-imidazol-
2-yl)amino)-N-(4-((4,5-dihydro-1H-imidazol-2-
yl)amino)phenyl)benzamide dihydrochloride (1) and
its chloro derivative (2) were performed following a
procedure described previously (3,6).
Crystallization. The crystal was grown by vapour diffu-
sion at 4◦C on hanging-drops. We used the following con-
ditions: a pre-incubated DNA-compound 1 complex in
sodium cacodylate buffer pH 6.0was added to the dropwith
final concentrations of 0.2 mMDNA duplex, 0.4 mM com-
pound 1, 25 mM sodium cacodylate buffer pH 6.0, 10 mM
magnesium acetate (Sigma), 0.1 mM spermine (Fluka) and
5% 2-methyl-2,4-pentanediol (MPD; Sigma-Aldrich); equi-
librated against a 20%MPD reservoir. MPD acts both as a
precipitant and a cryoprotectant. The concentration of the
reservoir was increased gradually up to 50%MPD. A single
crystal appeared after 14 months.
Data collection and structure determination. The crystal
was flash-frozen and stored in liquid Nitrogen. A PILA-
TUS 6M detector on beamline BL13-XALOC (28) at the
ALBA synchrotron, Barcelona, Spain was used for data
collection at 100 K and a wavelength of 0.979 A˚, with a
maximum resolution of 1.2 A˚. The data were integrated
using iMOSFLM (29) and scaled with Aimless Pointless
(30) from the CCP4 suite (31). The space group turned out
to be the monoclinic I121. A theoretical B-DNA model
was constructed usingTURBO-FRODO (http://www.afmb.
univ-mrs.fr/-TURBO-), with a base-pair stacking of 3.286
A˚, a uniform twist of 36◦ andWatson–Crick base-pair pair-
ing. It served as a starting search model for molecular re-
placement with MOLREP (32). Due to the lack of suc-
cess after an extensive search in different monoclinic space
groups, we generated another theoretical model formed by
half of the oligonucleotide and placed it in the correct posi-
tion by molecular replacement using Phaser (33). The miss-
ing base pairs of the oligonucleotide were added with Coot
(34) following thewell-defined electron diffractionmap. The
replacement was next refinedwithREFMAC5 (35) and real-
space refinement was performed with Coot. In this way we
placed one duplex and two single strands of DNA in the
asymmetric unit. The coordinates and stereochemical re-
straint dictionary of the compound 1 molecule were gener-
ated with Phenix (36), and one drug per duplex was placed
in the minor groove of the DNA structure using Coot. One
DNA duplex and two DNA single strands with three com-
pound 1molecules formed the final model. Several cycles of
maximum-likelihood isotropic restrained refinement were
performed with REFMAC5 to 1.247 A˚ resolution. Finally,
a last round of refinement with anisotropic restrictions was
completed to obtain the final values of Rwork = 0.1205 and
Rfree = 0.1668 in a resolution range of 36.137–1.247 A˚,
with a completeness of 92.54%. Four magnesium ions were
detected. Solution coordinates have been deposited in the
Protein Data Bank as PDB-ID: 5LIT. The DNA structural
parameters were calculated using the 3DNA software (37).
Drawings were prepared with PyMOL (http://www.pymol.
org) and CCP4mg (38).
Surface plasmon resonance (SPR)–biosensor experiments
The 5’-biotin labelled DNA hairpins were purchased
from Sigma-Aldrich with reverse-phase HPLC pu-
rification. The DNA hairpin sequences included 5’-
biotin-GGGAATAATCGCGATTATTCCCCAATAA
TCGCGATTATT [AATAAT ATTATT], 5’-biotin-
CGAATTCGTCTCCGAATTCG-3’ [AATT], 5’-biotin-
CATATATATCCCCATATATATG-3’ [(AT)4], and
5’-biotin-CGCGCGCGTTTTCGCGCGCG-3’ [(CG)4].
The oligomers were dissolved in 10 mM HEPES, 150 mM
NaCl, pH 7.4.
HMGB1 protein expression and purification. Plasmid
pGEX2T containing GST-tagged rat HMGB1 box A and
box B domains (Lys8–Lys165), kindly provided by Dr
M.E.A. Churchill (University of Colorado, USA) (39) (see
Supplementary Figure S2), was expressed inEscherichia coli
Rosetta(DE3)pLysS strain (Novagen). Protein expression
and purification was done as in (40).
HMGA1a 50-91 protein expression and purification.
Plasmid pET3a-HMG-I50–91 containing human
HMGA1a (amino acids 50–91) was kindly provided by
Dr R. Reeves (Washington State University, USA). This
fragment contains the AT-hook II and AT-hook III do-
mains of the protein (Supplementary Figure S2). AT-hook
domains allow the binding of the protein to the minor
groove of AT-rich DNA sequences. HMGA1a 50–91 was
expressed in Escherichia coli Rosetta(DE3)pLysS strain.
Cells were grown in LB medium containing ampicillin and
chloramphenicol at 37◦C with vigorous shaking. When the
absorbance at 600 nm reached 0.6, expression was induced
for 3 h with 1 mM IPTG. The bacterial cells were harvested
by centrifugation at 4000 rpm for 10 min. Bacterial pellets
were resuspended in ice-cold 5%HClO4/0.5% Triton X-100
and protein was precipitated with 25% TCA as described
by Reeves and Nissen (41). Protein was first purified by
cation-exchange chromatography using a CM52 (What-
man) column and a linear gradient to a final concentration
of 1 M NaCl in 25 mM Tris, pH 7.0. The purest fractions,
as assessed by SDS-PAGE, were pooled and concentrated
for a final purification via size-exclusion chromatography
(Superdex Peptide 10/300 GL, GE Healthcare) in 100
mM NaCl, 100 mM Tris, pH 7.5. Final pure samples were
dialysed in 25 mM HEPES, 50 mM NaCl, 1 mM DTT pH
7,4. The final protein concentration was calculated using
an extinction coefficient of 38 200 mol−1 cm−1 at 220 nm
(42).
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SPR-biosensor experiments: binding affinity and binding in-
hibition. SPR binding and competitive experiments were
performed at 25◦C with a Biacore X-100 apparatus (Bia-
core GE). HEPES 1 buffer containing 10 mM HEPES, 3
mM EDTA, 200 mM NaCl, and surfactant P-20 at 0.05%
(v/v) pH 7.4, was used for the competition experiments with
HMGA1a and HMGB1 proteins, and also for the dilution
of HMGA1a and HMGB1. The DNA hairpins were im-
mobilized on a streptavidin-derivatized gold chip (SA chip
from Biacore) by injection of a 25 nM hairpin DNA so-
lution with a flow rate of 1 l/min until ∼400 RU were
reached. Flow cell 1 was used as reference while flow cell
2 was immobilized with the hairpins in different chips. Di-
rect binding of HMGA1a and HMGB1 was measured by
injection of increasing concentrations of each protein over
the immobilized DNA surfaces at a flow rate of 50 l/min
for a period of 60 s followed by a dissociation period of
120 s. Regeneration of the surface was made with NaCl 200
mM/NaOH 10 mM using a flow rate of 10 l/min during
30 s. The binding affinity was determined by fitting the re-
sults to a two sites bindingmodel according to the equation:
r = (K1Cf + 2K1K2C2f )/(1 + K1Cf + K1K2C2f ),
where r is the moles of bound compound per mole of DNA
hairpin duplex, Cf is the free concentration at the equilib-
rium, and K1 and K2 the microscopic binding constants.
The competition experiments were prepared with sam-
ples containing a fixed concentration of HMGA1a and
HMGB1 proteins (2 M) and a series of concentrations of
compound 2 ranging from 0.05 to 200 M (for HMGA1a)
or 400 M (for HMGB1) in HEPES 1 buffer. The samples
were injected to the immobilized DNA surfaces at a flow
rate of 50 l/min for a period of 60 s followed by a dissoci-
ation period of 150 s. The regeneration conditions were sim-
ilar to the binding experiments described above. The bind-
ing responses (RU) at steady state were averaged and nor-
malized by setting the RU with the proteins HMGA1a and
HMGB1 alone as 100% binding to DNA and the RU with
saturation by the inhibitor as 0%. IC50 values were deter-
mined by fitting the inhibition data with a model according
to a competition system with 1:1 binding stoichiometry for
HMGA1a and HMGB1 and two site-binding for competi-
tor:
%proteins binding to DNA
= 100/ [1 + C(1 + Kc2C)/[IC50(1 + Kc2IC50)]]
where Kc2 is a macroscopic binding constant for inhibitor
binding to DNA, IC50 is the concentration of the inhibitor
that causes 50% inhibition ofHMGA1a andHMGB1 bind-
ing to DNA, and C is the concentration of inhibitor (43).
RESULTS
Functional analysis
Resistance profile of isometamidium-adapted cell line
ISMR1 and the parental cell line Tb427WT. As the
starting hypothesis was that kDNA might be a target for
compounds 1 and 2, they were tested in parallel against
the standard T. brucei laboratory strain Tb427WT and the
isometamidium-adapted cell line ISMR1 (19), which is
dyskinetoplastic, meaning that the strain has adapted to
the loss of its kinetoplast. In vitro drug sensitivity assays
established that ISMR1 was highly resistant to ISM when
the EC50 values of the resistant clone were compared to
those of the parent Tb427WT strain (Table 1). Significant
cross-resistance is displayed by ISMR1 to the compounds
1 and 2, with 127- and 132-fold increases in EC50 values,
respectively, indicating that the independence from kDNA
had made the cells resistant to the test compounds.
Compounds 1 and 2 alter the cell cycle of T. brucei. In the
T. brucei cell cycle, replication and division of kDNA nec-
essarily precedes nuclear division (44), and compounds that
directly impact on kDNAare thus expected to interfere with
cell division. Indeed, both compounds dose-dependently re-
duced T. brucei growth rates and, at concentrations above
EC50, appeared to induce growth arrest after 24 h (Figure
2A).
To analyze whether compounds 1 and 2 have an effect
on the cell cycle, the DNA content was measured by flow
cytometry, with emphasis on the ratio between cells with
G1 phase of cell cycle and those cells synthesising DNA (S
phase of cell cycle), as well as on the appearance of cells
in G2 phase. Moreover, in order to observe cell cycle pro-
gression in detail, i.e. to visualize DNA configuration from
nuclei and kinetoplast, fluorescence microscopy was car-
ried out. The results show a clear effect of the tested com-
pounds on the S phase of the cell cycle after 12 h and an
even more remarkable alteration after 24 h of incubation
(Figure 2B). The proportion of cells in G2 phases initially
showed a slight increase (at 12 h of treatment), and a small
reduction later (after 24 h), while an increase of cells in G1
phase was observed. The percentage of treated cells in S
phase decreased dose-dependently throughout the experi-
ment, whereas therewas no significant change in the S phase
for the control which maintained a normal growth rate (see
Supplementary Figure S3).
The cellular DNA configuration was assessed using the
dye DAPI for compound 1 and SYTOX Green nuclei acid
stain for compound 2 (as compound 2 fluoresces at a simi-
lar wavelength as DAPI). Cells exposed to the compounds
for 8 and 24 h were scored into the following standard
groups: 1N1K (one nucleus and one kinetoplast), 1N2K
(one nucleus and two kinetoplasts), 2N2K-E (two nuclei
and two kinetoplasts, but no clear furrow towards cell divi-
sion), 2N2K-L (two nuclei and two kinetoplasts when cells
were almost completely divided into two daughter cells).
Another group was added to the classification: 1N/2N (1
or 2 nuclei and no kinetoplast) due to the high incidence of
cells with such a DNA configuration after 8 h (Supplemen-
tary Figure S4) or 24 h of treatment (Figure 2C). In cells
treated with either compound, there was a dose-dependent
reduction in cells with one nucleus and two kinetoplasts, in-
dicative of a failure to initiate a new cell division cycle. Sim-
ilarly, the number of cells in the early stages of cell division,
with two kinetoplasts and nuclei, was approximately halved
after 24 h of exposure to the compounds. At the same time,
cells without any kinetoplast (1N/2N) started to appear in
the treated populations, having apparently concluded mi-
tosis despite the non-division of the kinetoplasts. In addi-
tion, completely aberrant cells (‘others’) also appeared in
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Table 1. Activity of compounds 1 and 2 against T. brucei 427WT and the isometamidium-resistant strain ISMR1
Compounds T. b. brucei 427WT T. b. brucei ISMR1 Resistance Factor vs. Tb247WT
EC50 (M) ± SEM EC50 (M) ± SEM
1 0.83 ± 0.08a 105.3 ± 3.2 127 ***
2 0. 220 ± 0.002a 29.0 ± 0.7 132 ***
Isometamidium 0.016 ± 0.001 1464 ± 94 92522 ***
EC50 values are given as mean of at least three independent determinations and SEM. The resistance factor (RF) is the ratio of the EC50 values of the
adapted strain and the wild-type control. Statistical significance was determined using a two-tailed unpaired t-test.
aReference (3). Asterisks represent P-values for statistically significant resistance, as calculated using a two-tailed unpaired Student’s t-test: ***, P-value
<0.0001.
Figure 2. (A) Growth curves of untreated control T. brucei 427WT and of parallel cultures treated with compounds 1 and 2 at 0.5, 1, 2 and 5 × their EC50
values. (B) Histograms of flow cytometric analysis of propidium iodide fluorescence associated with Tb427WT trypanosomes. The frames shown show
control and exposed (1 × and 5 × EC50) to 1 or 2 for 24 h, with most cells in G1 phase (blue peak, single set of chromosomes) and smaller numbers in
S-phase (green, DNA synthesis) and G2 phase (orange, 2 sets of chromosomes). (C) DNA content of cells treated 24 h with compounds 1 and 2 at 1 × and
5 × EC50 as determined by fluorescence microscopy (N, nucleus; K, kinetoplast; 1N/2N, cells with one or two nuclei but no observable kinetoplastid).
the treated cultures, which typically contained multiple nu-
clei and/or kinetoplasts, or none at all. The combined ev-
idence shows that 1 and 2 interfere with the normal pro-
gression of the T. brucei cell cycle, most likely by preventing
kinetoplast division.
Compounds 1 and 2 cause a slow decline in mitochondrial
membrane potential. Bloodstream forms of T. brucei were
cultured for up to 12 h in the presence and absence of com-
pounds 1 and 2, stained with TMRE and analysed by flow
cytometry for analysis of m. Valinomycin was used as
the control for depolarization and troglitazone as the con-
trol for hyperpolarization. The summary of the results of
three independent determinations of TMREfluorescence of
treated and untreated cells with 1 and 2 for 3, 6 and 12 h is
shown as a line graph in Figure 3. Histograms of one de-
termination are shown in Supplementary Figure S5. Values
are given as the percentage of cells with fluorescence above
100 arbitrary units (A.U.), which was set to approximately
50% for the controls. A shift to higher fluorescence signifies
increased m; lower fluorescence signifies depolarization
of the mitochondrial membrane; for the untreated cell cul-
ture,m remained stable for the duration of the experiment,
at approximately 50%. Compounds 1 and 2 dose depen-
dently, progressively reduced m, with only minor effects
at 3 h but significantly progressing by 6 h, and a clear, dose-
dependent depolarization of the m evident at 12 h (Figure
3). The data are consistent with mitochondrial targeting of
the compounds as cations, but their effect on the membrane
potential is slower than has been reported for some other
compounds such as bisphosphonium salts, which appeared
to impact directly on the FoF1-ATPase (20).
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Figure 3. Effect of compounds 1 and 2 on mitochondrial membrane po-
tential (m) of T. b. brucei s427-WT. The results shown are the mean of
three independent determinations; error bars depict standard errors. The
inset table lists the P values, using a Student’s two-tailed, unpaired t-test
comparing each category to the untreated control, incubated for the same
length of time; a value <0.05 is considered to be significant. Untreated
cells (drug free), valinomycin (negative - depolarization) and troglitazone
(positive - hyperpolarization) are employed as controls.
Fluorescent compound 2 accumulates in the mitochondrion
of trypanosomes. In order to study the cellular distribu-
tion of the bis(2-aminoimidazolinium) compounds, we in-
cubated cells with the fluorescent compound 2 (emission:
450 nm), using the green-fluorescent SYTOX Green nu-
cleic acid stain (excitation/emission: 504/523 nm) to visu-
alise the nuclei and kinetoplasts. We further visualized the
T. bruceimitochondrion with the red-fluorescent dye Mito-
Tracker Red CMXRos (excitation/emission: 579/599 nm),
which produces a highly specific stain ofT. bruceimitochon-
dria (45,46). After 3 h of exposure, compound 2 can just be
detected inside of the cell but no particular distribution is
discernible (Figure 4). After 6 h, compound 2 shows a ho-
mogeneous distribution throughout the cytoplasm, and is
becoming concentrated in the mitochondria. At that mo-
ment, the kinetoplast is no longer visible in many of the
cells, although the SYTOX Green still strongly highlights
the nuclei. After 24 h of treatment, compound 2 seems to be
even more concentrated in the mitochondrion with intense
spots of the fluorescence coinciding with the most intense
MitoTracker staining; kinetoplast staining with SYTOX
was absent from almost all cells. In untreated cells grown
in parallel, no changes in fluorescence were observed at
the blue wavelength that visualized 2, and there were no
changes to kinetoplast DNA staining (see Figure 4).
Figure 4. Fluorescence localization of the compound 2 in Trypanosoma
brucei s427-WT cells. Images were taken at 3, 6 and 24 h of incubation with
5 M compound 2. Untreated cell samples were taken at each time point
for drug free control. All fluorescent images are shown with compound 2
( = 450, blue channel), SYTOX Green ( = 523, green channel), Mito-
Tracker ( = 599, red channel), and merge, where arbitrary colors were
used to visualize the various dyes: blue for 2, purple for SYTOX, yellow
for Mitotracker. The outline of all cells is shown by differential interfer-
ence contrast (DIC) imaging. Images were acquired using a DeltaVision
imaging system and deconvolved using the ratio conservative method, on
SoftWoRx software.
Compounds 1 and 2 cause destruction of the kinetoplast DNA
network. Transmission electron microscopy (TEM) was
used to study the trypanosomes’ ultrastructure after expo-
sure to 5 M compounds 1 and 2 to analyze the effects
of these compounds on the cellular structure of the para-
site. Based on the information obtained with the cellular
localization of the compounds in the cell by fluorescence
microscopy, TEM samples were taken after 3 and 24 h in-
cubation, as ‘early’ and ‘late’ time points to determine the
structural effects of the compounds.
Analyzing the images obtained with TEM (shown in
Figure 5), we can confirm that compounds 1 and 2 have
the same mechanism of action in the cell. Both com-
pounds cause ultrastructural abnormalities in the kineto-
plast, which were clearly far more severe at 24 h than at
3 h of incubation, when many cells appeared still undam-
aged, i.e. the drug has not yet impacted on the kinetoplast
(top row images at 3h of 1 or 2, Figure 5). However, differ-
ent cells in the same population show dark dots or empty
space inside the kinetoplast (bottom row of same columns;
arrows indicate the abnormalities), which confirm an initial
level of damage in the kDNA of some cells during the first
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Figure 5. TEM images showing normal ultrastructure of bloodstream form for treated and untreated (drug free control) cells of Tb427-WT after incubation
with compound 1 or compound 2 for either 3 h or 24 h. F = flagellum, FP = flagellum pocket, k = kinetoplast. Images were observed in a Tecnai T20
(FEI) at 200 kV. Irregular structures in the kinetoplast are shown with arrows and arrowheads, indicating kDNA damage.
3 h exposure with the compounds. After 24 h of treatment
with compounds 1 and 2, all cells displayed clear damage
to kinetoplasts, which has completely lost the characteristic
disk-like structure of uniform electron-density, a structure
of intercalating minicircles and maxicircles that is essential
for both the functioning and replication of the kinetoplast
(47). This is completely consistent with the lack of kDNA
staining observed with SYTOX Green (see Figure 4) and
we conclude that at 24 h the mitochondrial DNA is largely
absent and completely disorganised. Since no other struc-
tures were found to be affected at the times the samples were
taken, we conclude that they directly affect the kinetoplast.
Compounds 1 and 2 show curative activity in a mouse model
of first stage HAT. The in vivo activity of 1 assessed earlier
showed that this compound is 100% curative in the mouse
model of acute T. b. rhodesiense infection by intraperitoneal
(4 × 5 mg/kg/day) and oral (4 × 50 mg/kg/day) dosage
(4,6). Here, we assayed the in vivo activity of the chloro ana-
logue 2 against T. b. rhodesiense in the same mouse model.
The intraperitoneal administration of 2 at 4× 4 mg/kg/day
increased themean day of relapse of parasitemia (17.5 days)
in mice although no cures were obtained. However, a 5-fold
higher dosage (4× 20mg/kg/day i.p.) provided a 100% cure
rate in this mouse model of stage 1 HAT.
Binding analysis
SPR-biosensor experiments.
Compounds 1 and 2 bind DNA at AT-rich sites. The bind-
ing affinity of compounds 1 and 2 to dsDNA containing
GGAATAATCGCGATTATTCC [AATAAT ATTATT],
CGAATTCG [AATT], CATATATAT [(AT)4], and
CGCGCGCG [(CG)4] sequences was determined by
surface plasmon resonance (SPR)-biosensor experiments
(Table 2). Compounds 1 and 2 bound selectively to AT-
containing DNA versus CG-containing DNA (from >10-
fold to >60-fold). Binding curves of both compounds were
adjusted to a two-sites affinity model where primary bind-
ing constants were in the submicromolar range with slight
selectivity toward AATT versus (AT)4 (1.8- to 2.5-fold) or
AATAAT ATTATT oligonucleotides (1.6- to 3-fold). With
the dsDNA containing GGAATAATCGCGATTATTCC,
compounds 1 and 2 displayed submicromolar primary
binding constants (high affinity binding site) and a 133-
and 48-times weaker secondary binding constants, respec-
tively. In these experiments, secondary binding generally
accounts for non-specific binding interaction with the
DNA hairpin loop as previously reported (4).t
Compound 2 inhibits the binding of high mobility group
proteins HMGA1a and HMGB1 to AT-rich DNA. The
AT-rich sites of DNA are typically recognised by AT-
hook proteins such as HMGA1a (48). In contrast,
HMGB1 binds more non-specifically to DNA. The sen-
sorgrams of HMGA1a and HMGB1 binding to the
AATAAT ATTATT oligonucleotide are shown in Figure 6.
In our experiments, HMGA1a(50–91) and HMGB1 pro-
teins showed a high affinity binding site to theAT sequences
of the AATAAT ATTATT oligonucleotide and a weaker
secondary binding site that most likely accounts for non-
specific binding to the hairpin loop (K2/K1 = 32 and 18, for
HMGA1a(50–91) andHMGB1, respectively). The higher
affinity of HMGB1 to this nonspecific secondary binding
site is compatible with this hypothesis. The KD values and
binding behavior of both proteins were similar to that of
compounds 1 and 2 (Table 2).
Competition assays were performed to test the capac-
ity of 2 to inhibit the formation of HMGA1a–DNA and
HMGB1–DNA complexes (Figure 7). Solutions of fixed
concentration of HMGA1a(50–91) or HMGB1 proteins
(2 M) in the presence of increasing concentrations of 2
were injected over the DNA immobilised surface. The sen-
sorgrams showed a clear decrease in RU signal when in-
creasing the concentration of 2 indicating a dose-dependent
inhibition of HMGA1a and HMGB1 binding to DNA
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Table 2. DNA binding constants determined by SPR for dsDNA containing AATAAT ATTATT, AATT, (AT)4 and (CG)4 sequences‡
KD (× 10−6M)a
dsDNA dsDNA dsDNA dsDNA
GGAATAATCGCGATTATTCC CGAATTCG CATATATAT CGCGCGCG
HMGA1a (50–91) K1 = 0.35 ndb nd nd
K2 = 11.3
HMGB1 K1 = 0.33 nd nd nd
K2 = 5.91
1 K1 = 0.56 K1 = 0.166c,d K1 = 0.307d > 10d
K2 = 74.7 K2 = 207 K2 = 20.91
2 K1 = 0.43 K1 = 0.262 K1 = 0.65 K = 6.85e
K2 = 20.8 K2 = 230 K2 = 39
‡dsDNA hairpins used in the study (the loop is underlined): 5’-biotin-GGGGAATAATCGCGATTATTCCCCAATAATCGCGATTATT
[AATAAT ATTATT], 5’-biotin-CGAATTCGTCTCCGAATTCG-3’ [AATT], 5’-biotin-CATATATATCCCCATATATATG-3’ [(AT)4], and 5’-
biotin-CGCGCGCGTTTTCGCGCGCG-3’ [(CG)4].
aBinding constants for fitting to a two-site binding model.
bNot determined.
cPrimary binding constant for fitting to a two-site binding model. The secondary binding constant (K2) corresponds to nonspecific binding to the hairpin
loop (62).
d(10).
eBinding constant for fitting to a one-site binding model.
Figure 6. (A) SPR sensorgrams of HMGA1a (top left panel)
and HMGB1 (top right panel) binding to dsDNA biotin-
GGGGAATAATCGCGATTATTCCCCAATAATCGCGATTATT
in HEPES 1 at 25◦C. For HMGA1a, the best sensorgrams were obtained
in HEPES 1 buffer, instead of MES or Phosphate buffer (43). (B) Binding
curves for interaction of HMGA1a (lower left panel) and HMGB1 (lower
right panel) with target DNA and fitting curve for a two-site affinity
model.
(Figure 7). IC50 values, determined by fitting the inhibition
data with a model according to a competition system with
1:1 binding stoichiometry for HMGA1a and HMGB1 and
two site-binding for competitor (43) were in the low micro-
molar range (6.0 and 3.4 M for HMGA1a and HMGB1,
respectively). We conclude that compound 2 competes with
HMGA1a and HMGB1 binding to DNA and it is able to
displace the proteins from its binding sites.
Structural analysis
Structure of the DNA–compound 1 complex. The crys-
tal structure solved at atomic resolution of 1.25 A˚ of the
DNA oligonucleotide [AAATTT]2 in complex with the
Figure 7. (A) SPR competition sensorgrams showing the inhibition of a
fixed concentration (2 M) of HMGA1a (Top left panel) and HMGB1
(top right panel) binding to dsDNA containing AATAAT ATTATT
oligonucleotide in the presence of increasing concentration of 2. Concen-
tration range from 0.05 to 200M(forHMGA1a) and 0.05 to 400M(for
HMGB1). (B) Inhibition curves and IC50 values for inhibition of binding
of HMGA1a (lower left panel) andHMGB1 (lower right panel) to dsDNA
by compound 2.
compound 1 is packed in space group I212. A summary of
crystal data and refinement statistics is given in Table 3.The
asymmetric unit contains three compound 1molecules (two
of them show half-occupancy), plus one DNA duplex and
two DNA single strands. Three complete duplexes and
three drug molecules are shown in Figure 8. The duplexes
are stacked and organised as infinite continuous paral-
lel columns, which are packed in a pseudo-tetragonal way
(Supplementary Figure S6). The drugmolecules fill the cen-
tral part of the minor groove of the duplexes. The crys-
tal is stabilized in part by the interaction of the central
molecule, drug F (pink) with theDNAphosphates of neigh-
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Figure 8. (A) View of the different crystallographic units of the complex. The black lozenge indicates the dyad axes. There are four independent single
oligonucleotides chains; two of them (blue-green) form the central duplex and the other two (orange and red) form two different DNA duplexes with their
symmetrical chain. Three crystallographically independent drug molecules are indicated in different colours. Drug F (pink), Drugs E (green) and G (blue).
(B) Hydrogen bonds formed by the drugs with the minor-groove atoms of the DNA duplexes show similar interactions. The orientation of the aromatic
rings in the central drug (F, pink) differs from to the other two drugs. Drug E and G have two possible inverted positions in the groove; for clarity only one
of them is shown.
boringmolecules, shown in Supplementary Figure S6.Drug
G (blue) and E (green) do not participate in the interactions
with neighbor DNA duplexes.
Drug conformation and interactions. The asymmetric unit
contains one molecule of drug F, one half-occupancy drug
E and one half-occupancy drug G. All of them interact in
the middle of the DNA duplex, the central AATT sequence,
as found in several other cases (49). Drug E and G are prac-
tically identical (r.m.s. differences of 0.172 A˚). Both drugs
form three hydrogen bonds: with two consecutive thymines
from one DNA strand (T4 and T5) and another thymine 5
from its symmetric strand, as shown in Figures 8 and 9. Val-
ues are given in Supplementary Table S1, available as Sup-
plementary data. The nitrogen atoms that are not hydro-
gen bonded toDNA are associated with water molecules, as
shown in Figure 9. The central drug molecule F has maxi-
mum r.m.s. differences of 1.250 and 1.269 A˚with drugE and
G, respectively. Drug F forms also three hydrogen bonds
with DNA: adenine 3 and thymine 5, both from chain A,
and T4 from chain B.Moreover, the drugmolecules are well
positioned and centered in their corresponding duplex, al-
lowing that the central nitrogen atom (N3) interacts with
the oxygen from thymine 4 [O2(T4)] either in the 3’-5’ direc-
tion (drug F with chain B) or in the 5’-3’ direction (drugs G
and E) (Figure 9). A remarkable feature of this drug is its
interactions with two phosphates from neighboring DNA
molecules, as shown in Supplementary Figure S6 and Table
S1. These cross-linking interactions contribute to stabilise
the crystal lattice.
DNA structure. The three different DNA duplexes in the
structure have similar and standard conformational param-
eters. The main difference is found in the twist angles in
the pseudo base step T-A between the ends of neighbor du-
plexes in oligonucleotide columns, see Figure 8. As found
in previous studies (50) the twist angle value is negative (-
21◦) at the contacts between oligos A-B and D-D’. Never-
theless, a peculiar feature of the present structure is the pos-
itive twist angle (29◦) between oligos A-B and C-C’, allow-
ing these two oligonucleotides form a pseudo-continuous
B-DNA helix. These differences are probably due to pack-
ing constraints induced by interactions between neighbor-
ing duplexes, see Supplementary Figure S6.
Predicted structural changes of the crystal with compound 2.
In order to analyse the interactions of the chloro deriva-
tive 2 (Figure 1) with DNA in our solved crystal structure,
the hydrogen atom in ortho to the right-hand imidazoline
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Figure 9. Schematic representation of interactions between F and G or E drugs and d[AAATTT]2. In the crystal, drugs G and E may be found in two
alternative positions, up and down, which are structurally identical. Symmetric chains are indicated with apostrophe.
Table 3. Data collection and refinement statistics
Data collection
Beamline BL13-XALOC, ALBA
Wavelength 0.997949
Resolution range (A˚) 36.14–1.25 (1.279–1.25)
Space group I121
Unit cell parameters (A˚, ◦) a = 22.33, b = 40.25, c = 72.42,
 = 90.00  = 93.67  = 90.00
Total reflections 245 821 (22 828)
Unique reflections 16 801 (1594)
Multiplicity 14.7 (14.2)
Completeness (%) 92.54 (90.67)
Mean I/sigma(I) 14.1 (5.5)
Wilson B-factor 9.90
R-merge † 0.069 (0.227)
Refinement statistics
Reflections used in refinement 15 741 (1122)
Reflections used for R-free 850 (89)
R-work ‡ 0.1205 (0.141)
R-free § 0.1668 (0.200)
Number of non-hydrogen atoms 730
DNA 480
Compound 1 81
Water 165
Mg2+ 4
RMS (bonds) 0.022
RMS (angles) 2.52
Average B-factor, all atoms (A˚2) 13.0
DNA 10.43
Compound 1 10.33
Water 22.38
PDB-ID 5LIT
Statistics for the highest-resolution shell are shown in parentheses.
†Rmerge= hkl i |Ii(hkl) - (Ii(hkl))| / hkl i Ii(hkl).
‡Rwork and Rfree were calculated as R = hkl | lFobsl - lFcalcl / hkl lFobsl.
§Rfree is the R factor evaluated for the reflections (5%) used for cross-
validation during refinement.
ring was replaced with a chlorine atom. The compound 2
could adopt the equivalent place as compound 1 in the mi-
nor groove of the DNA duplex. Unexpectedly, the position
of the chlorine atom in compound 2 prevents the interac-
tion with the neighbouring DNA molecules (Supplemen-
tary Figure S7), and therefore, the crystal packing would
probably change to a C2 space group.
DISCUSSION
In kinetoplastid parasites the mitochondrial DNA is or-
ganised as a tightly packed disk of maxicircles (up to ∼23
kb) with thousands of minicircles of approximately 1 kb
(51). It has been argued that, because dyskinetoplastic try-
panosome species exist and dyskinetoplastic strains can be
selected for under laboratory conditions, the kinetoplast
may not be a valid target for drugs against trypanosomia-
sis. Yet, although theT. b. bruceimitochondrion is relatively
stripped-down in its long-slender bloodstream form com-
pared to other life-cycle stages, it retains essential functions
and some essential proteins, including the A6 subunit of the
FoF1 ATPase, which are encoded by kDNA (52). It has now
been shown that survival of the loss of kDNA requires a
compensatorymutation in the nuclearly-encoded  -subunit
of the same ATPase (53). This showed that, although adap-
tation to the loss of kDNA is possible in trypanosomes, it
requires a rare event, and that any drug causing the rapid de-
struction or disorganization of the mitochondrial genome,
such as homidium or isometamidium (54), can be highly
effective. Trypanocidal dications such as diamidines and
bisimidazolinium compounds have long been speculated to
act on mitochondrial targets (21,55) and some clearly bind
to DNA (8,17,56). However, although their abilities to act
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as minor groove binders are well established, it is much less
clear whether this is necessarily the principal trypanocidal
mode of action, and whether binding to kDNA and/or nu-
clear DNA contributes most to cell death. Here, we present
the most comprehensive analysis to date that one class of
aromatic dications, the bis(2-aminoimidazolines), directly
act on the kinetoplast and cause its rapid disintegration.
We have paid special attention to the kinetoplast since
significant resistance (>100-fold) by the dyskinetoplastic
cell line ISMR1, relative to the wild type cell line, indicated
the kinetoplast as a probable target of compounds 1 and
2. Moreover, a study of the T. brucei cell cycle by flow cy-
tometry showed that incubation with the test compounds
caused a progressive cell cycle arrest in G1 phase, reflected
in the major decrease in S-phase cells after 24 h. The fail-
ure to initiate DNA synthesis was almost certainly the re-
sult of damage to the kinetoplast, as kinetoplast division
necessarily precedes nuclear division (57), and both fluo-
rescence microscopy and TEM showed major damage to
the kinetoplast but not to the nucleus. Starting at just 8 h,
a significant numbers of cells were found without an ob-
servable kinetoplast or with 1 kinetoplast and two or even
three nuclei - clear evidence of a defect in kinetoplast repli-
cation. By 24 hours this was leading to the gross destruc-
tion and/or disorganisation of the kinetoplast as observed
by TEM and concomitant growth arrest; importantly, the
electron microscopy did not reveal any damage to the nu-
clei or other cellular structures. Despite the absence of ul-
trastructural damage to the mitochondrion, the membrane
potential m began to decrease from 6 h of incubation.
In bloodstream trypanosomes, which lack the common ox-
idative phosphorylation complexes, m is generated by the
FoF1 ATPase pumping protons from themitochondrialma-
trix, using ATP (53,58,59); clearly this process would pro-
gressively be impeded as the lack of functional kDNA pre-
cludes the production of the A6 subunit of Fo, leading
to the slow membrane depolarisation observed. Accumu-
lation of cationic compounds in the mitochondria, driven
by the negative electrostatic potential (negative inside), is
a well-described phenomenon for cationic and dicationic
compounds (18,20,60), but the relatively slow effect of com-
pounds 1 and 2 on the m compared with that of com-
pounds that act directly on the F1F0-ATPase complex (20)
is consistent with the hypothesis that the antiparasitic effect
derives from preventing the accurate replication of kDNA
and consequently the assembly of F0.
The interaction of 1 and 2 directly with DNA was con-
firmed by structural and binding analyses of the drug-DNA
complex at the molecular level. The study of the crystal
structure of compound 1 in complex with the all-AT DNA
sequence d[AAATTT]2 at atomic resolution of 1.25 A˚ re-
vealed important features (structure shown in Figure 8;
electronic map is displayed in Supplementary Figure S8);
The compound covers the minor groove of the DNA du-
plexes stacked in columns, with one compound per duplex
filling the central part of the minor groove (AATT). Com-
pound 1 may interact with DNA in several alternative po-
sitions (molecule F, G and E), which confirms its affinity
for the common kDNA sequence AATT. Furthermore, we
report a new mode of interaction and packing of a minor
groove binding drug with DNA due to the space group
I212 and the formation of hydrogen bonds with neigh-
bouring DNA molecules. Such interactions help to stabi-
lize the DNA structure of the stacked duplexes, and may
be particularly interesting in the highly organised, densely
packed kinetoplast of intercalating minicircles and maxi-
circles, preventing the correct separation and unwinding,
that is required for the correct replication of each of thou-
sands of minicircles (47). Further confirmation that 1 and
2 are strong DNA binders and specifically target AT- over
GC-rich sites was obtained using SPR. These experiments
confirmed binding constants in the low micromolar range,
which are easily achieved bymitochondrial accumulation of
cationic compounds (20,61).
The formation of a DNA-drug complex may disrupt the
function of kDNA-binding proteins in trypanosomes, such
as HMG-box proteins, topoisomerases, etc. As mentioned
in the Introduction, the TbKAP6 protein has two HMG-
boxes (Supplementary Figure S9) essential for kDNA repli-
cation and maintenance (23). We therefore investigated
whether the bis(2-aminoimidazolinium) compounds could
potentially compete with HMG-box proteins for binding
to DNA. We found that compound 2 is able to displace
HMGB1 (and also HMGA1a) proteins from their DNA
binding sites. This could potentially be the first event in the
process leading to the malfunctioning of cell cycle progres-
sion and the disruption of the kDNA organisation. Indeed,
all the evidence accumulated in this work shows that com-
pounds 1 and 2 target kDNA, leading to the destruction
of the kDNA arrangement and growth arrest. As such, the
prevention of HMG proteins binding to kDNA could very
well contribute to their observed antitrypanosomal effect
alongside the likely disruptive effect that the strong bind-
ing of the compounds to AT-rich kDNA could also have on
kDNA replication.
Altogether, these results show that the N-
phenylbenzamide bis(2-aminoimidazolinium) compounds
1 and 2 share the same mechanism of action against
Trypanosoma brucei, acting specifically on the integrity of
the kinetoplast by altering the structure and replication of
kDNA. As both compounds show 100% curative activity
in a mouse model of T. b. rhodesiense infection, they have
potential as effective chemotherapeutic agents for the
treatment of sleeping sickness.
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